KRYS Krystal Biotech, Inc. Insider Trading

Suma Krishnan (President, R&D) sold 25,000 shares for $7.7M via scheduled 10b5-1 plan on 2026-06-04

Suma Krishnan executed 11 separate sales totaling 25,000 shares for $7,702,825.22 on 2026-06-04 at a blended average price of $308.11, reducing his holdings from 1.40M to 1.38M shares (-1.8%). This transaction is governed by a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, making it a scheduled execution rather than a discretionary trade. The sell occurred near KRYS's 52-week high of $319.48 (current price $301.00, down 5.8% from peak), and in the context of his same-ticker history at KRYS, prior sales in March 2026 showed modest 30-day returns (ranging -1.4% to +1.4%) but consistently positive 90-day outcomes (+10.8% to +14.0%). With KRYS trading at a 39.45 P/E and demonstrating strong fundamentals (annual revenue growth of +33.9%, latest quarter revenue of $116.4M and net income of $55.9M), the liquidation reflects execution of a pre-planned schedule rather than a signal about conviction in the company's trajectory.

KRYS CEO Krishnan sold 25,000 shares for $7.7M (avg $308.12) via scheduled 10b5-1 plan on 2026-06-04

Krish S Krishnan, President and CEO of Krystal Biotech, executed 11 separate sales totaling 25,000 shares for $7,702,983.82 on 2026-06-04, reducing his holdings from 1,475,253 shares to 1,450,253 shares (a -1.7% net change). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it was scheduled rather than discretionary. The blended average sale price was $308.12, slightly above the current price of $301.00. The company's fundamentals show strong growth (annual revenue growth of +33.9%) and profitability (net income of $55,932,000.00 on revenue of $116,357,000.00 in the latest quarter), though the P/E ratio of 39.45 reflects investor expectations. Given the scheduled nature of the transaction under a 10b5-1 plan, this sale does not convey timing-dependent signals; it represents predetermined portfolio activity that proceeded regardless of current market conditions.

President of R&D sold 25,000 shares at blended $263.21; stock now at $253.69, -13.1% from high

Krishnan Suma, President of R&D at Krystal Biotech, executed 10 separate sales totaling 25,000 shares for $6,580,270.42 on 2026-03-04, reducing holdings from 1,428,155 to 1,403,155 shares (-1.8%). The sales occurred at prices ranging from $257.32 to $266.42, with a blended average of $263.21, versus the current price of $253.69. The stock is currently -13.1% from its 52-week high of $291.93. At the same ticker, Suma's prior five trades (all sales on 2025-12-04) posted 90-day returns ranging from +19.5% to +23.7%; none were well-timed at the 90-day mark. His cross-ticker track record across 20 prior sales shows an average 90-day return of +21.8% with a 0.00% well-timed rate, indicating a consistent pattern of selling before price increases rather than declines. The company reports strong recent fundamentals: quarterly revenue of $97,800,000.00, net income of $79,365,000.00, annual revenue growth of +33.9%, and a P/E of 23.58.

CEO Krishnan sold 25,000 shares for $6.6M via 10 separate transactions on 2026-03-04 under pre-arranged 10b5-1 plan

Krishnan Krish S, President and CEO, executed 10 separate sales totaling 25,000 shares for $6,579,164.35 across a blended average price of $263.17 on 2026-03-04. This represents a -1.7% reduction in his holdings to 1,475,253 shares. The transaction was conducted under a 10b5-1 trading plan adopted on 2025-09-04, making it a scheduled, non-discretionary sale. The multiple tranches at incrementally rising prices ($257.31 to $266.56) reflect algorithmic execution rather than a single block trade. Since the sale is pre-arranged and scheduled, no inference about CEO confidence or market timing can be drawn from this filing alone.

Director Daniel Janney sells 11,803 shares for $3,252,824.34 via pre-arranged 10b5-1 plan

Director Daniel Janney executed 2 separate sales totaling 11,803 shares for $3,252,824.34 on 2026-02-27 at blended average price of $275.59, reducing holdings from 85.1K shares to 73.3K shares (-13.9% of pre-transaction holdings). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled in advance rather than discretionary. The magnitude represents a material reduction in his personal stake, though holdings remain substantial at 73,293 shares post-transaction. Investors should note that 10b5-1 transactions execute on predetermined schedules independent of market conditions or company developments.

Director Daniel Janney sold 60,161 shares for $16,149,383.09 at KRYS on 2026-02-24/25/26 via 10b5-1 plan

Daniel Janney, a Director at Krystal Biotech, executed 20 separate sales totaling 60,161 shares for $16,149,383.09 across February 24–26, 2026, reducing his holdings by 41.4% from 145,257 to 85,096 shares. These transactions were part of a pre-arranged 10b5-1 trading plan, meaning they were scheduled rather than discretionary. The sales occurred across a narrow price range (blended average $268.44, with individual transactions ranging from $262.91 to $276.32), suggesting execution against accumulated demand at relatively stable levels. The magnitude of this reduction—disposing of more than two-fifths of holdings—represents a material decrease in the director's equity stake, though the scheduled nature of the plan indicates these sales were committed in advance rather than responsive to current events.

Director Rossi sells 18,950 shares for $4,953,694.15 in two transactions at $260.49–$262.10; retains 78,691 shares post-sale.

Director Dino A Rossi executed two separate sales on 2026-02-19, disposing of 18,950 shares (19.0K shares) for a combined $4,953,694.15 at a blended average price of $261.41. The reduction represents a 19.4% decrease from his pre-transaction holding of 97,641 shares (97.6K shares), leaving him with 78,691 shares (78.7K shares) post-sale. The sale occurred while the stock is trading at $274.59 current price, approximately 5.9% below its 52-week high of $291.93. Against a strong operational backdrop—Krystal Biotech reported $97.8M in latest-quarter revenue with $79.4M net income and 33.9% annual revenue growth—this material reduction in the director's position represents a significant holding adjustment at valuations that remain well within the stock's recent range.

CAO Kathryn Romano sold 12,500 shares for $3,401,705.16 via scheduled 10b5-1 plan

Kathryn Romano, Chief Accounting Officer at Krystal Biotech, executed 7 separate sales totaling 12,500 shares for $3,401,705.16 at prices ranging from $270.56 to $277.88 on 2026-02-09, reducing her post-transaction holdings to 18,568 shares (a -40.2% reduction from pre-transaction holdings of 31,068 shares). This sale was conducted under a pre-arranged 10b5-1 trading plan, meaning the transaction was scheduled and not subject to discretionary timing. The blended average price across the transactions was $272.14. As a scheduled disposition under Rule 10b5-1, this filing reflects a prearranged program rather than a signal of current executive sentiment regarding valuation or company prospects.

KRYS President of R&D Krishnan Suma sells 50,000 shares for $11.0M via scheduled 10b5-1 plan adopted 2025-09-04

Krishnan Suma, President of R&D at Krystal Biotech, executed 16 separate sales totaling 50,000 shares for $11,007,332.86 at a blended average price of $220.15 on 2025-12-04. This transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning the sales were scheduled and not discretionary. The sales reduced his holdings from 1,528,056 shares to 1,478,056 shares, a reduction of 3.3% of pre-transaction holdings, leaving him with substantial remaining equity exposure. Since this sale was executed under a pre-established trading plan, it does not reflect real-time decision-making or a change in conviction; it represents a mechanical execution of a plan adopted approximately three months prior.

KRYS CEO Krishnan sold 50,000 shares for $11.0M on 2025-12-04 via pre-arranged 10b5-1 plan adopted 2025-09-04

Krishnan Krish S, President and CEO of Krystal Biotech, executed 16 separate sales totaling 50,000 shares for $11,007,446.72 on 2025-12-04, reducing his holdings from 1,463,711 shares to 1,413,711 shares (a 3.4% reduction). The sales occurred across a range of prices from $214.25 to $222.38, with a blended average price of $220.15. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-04, meaning it is scheduled rather than discretionary. The CEO retains substantial holdings of approximately 1.41M shares post-transaction, indicating continued material equity stake in the company.